@article {44727,
	title = {Circulating exosomal miRNAs: clinical significance in human cancers},
	journal = {Expert Reviews of Molecular Diagnostics},
	volume = {19},
	number = {11},
	year = {2019},
	note = {Avgeris, MargaritisPanoutsopoulou, KonstantinaPapadimitriou, Maria-AlexandraScorilas, AndreasengResearch Support, Non-U.S. Gov{\textquoteright}tReviewEngland2019/10/09 06:00Expert Rev Mol Diagn. 2019 Nov;19(11):979-995. doi: 10.1080/14737159.2019.1673732. Epub 2019 Oct 20.},
	month = {Nov},
	pages = {979-995},
	abstract = {Introduction: The identification of novel noninvasive biomarkers to ameliorate early-diagnosis, and disease prognosis, as well as to support personalized treatment and monitoring decisions is of first clinical priority for cancer patients{\textquoteright} care. Exosomes are natural endosome-derived extracellular vesicles that have emerged as crucial mediators of intercellular communication and tumor progression. Considering that deregulated miRNA levels have been described in numerous human malignancies and that tumor-derived exosomes reflect miRNA expression of donor tumor cells, the evaluation of exosome-derived circulating miRNAs (exomiRs) may offer a new promising class of noninvasive molecular markers to improve patients{\textquoteright} management and quality-of-life. Areas covered: In the current review we have summarized the existing knowledge on the clinical relevance of circulating exosomal miRNAs in improving cancer diagnosis and prognosis, and thus supporting personalized patients{\textquoteright} management Expert commentary: Cancer research has highlighted the abundance of exomiRs in patients{\textquoteright} plasma and serum samples, as well as their biomarker capabilities in the vast majority of human malignancies studied so far. Their analytical stability constitutes exomiRs ideal molecular markers to overcome numerous limitations of cancer clinical management, while future large-scale studies should unveil exomiRs translational utility in modern cancer molecular diagnostics.},
	keywords = {Antineoplastic Agents/administration \& dosage/adverse effects/therapeutic use, Biomarkers, Tumor/*blood/genetics, Circulating MicroRNA/*blood/genetics, circulating miRNA, exomiR, exosomes, Exosomes/*genetics, Humans, Neoplasms/*blood/diagnosis/drug therapy, non coding RNA, noninvasive biomarkers},
	isbn = {1744-8352 (Electronic)1473-7159 (Linking)},
	author = {Avgeris, M. and Panoutsopoulou, K. and Papadimitriou, M. A. and Scorilas, A.}
}
